AR110101A1 - Miembros de unión (2) - Google Patents

Miembros de unión (2)

Info

Publication number
AR110101A1
AR110101A1 ARP170101707A ARP170101707A AR110101A1 AR 110101 A1 AR110101 A1 AR 110101A1 AR P170101707 A ARP170101707 A AR P170101707A AR P170101707 A ARP170101707 A AR P170101707A AR 110101 A1 AR110101 A1 AR 110101A1
Authority
AR
Argentina
Prior art keywords
seq
antibody molecule
lag
molecule according
binding site
Prior art date
Application number
ARP170101707A
Other languages
English (en)
Spanish (es)
Inventor
Katarzyna Kmiecik
Matthew Kraman
Miguel Gaspar
Katy Louise Everett
Van Horck Francisca Wollerton
Mihriban Tuna
Nikole Sandy
Jamie Campbell
Barbara Hebeis
Natalie Allen
Mustapha Faroudi
Original Assignee
F Star Delta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Delta Ltd filed Critical F Star Delta Ltd
Publication of AR110101A1 publication Critical patent/AR110101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP170101707A 2016-06-20 2017-06-21 Miembros de unión (2) AR110101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662352482P 2016-06-20 2016-06-20

Publications (1)

Publication Number Publication Date
AR110101A1 true AR110101A1 (es) 2019-02-27

Family

ID=59631719

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101707A AR110101A1 (es) 2016-06-20 2017-06-21 Miembros de unión (2)

Country Status (25)

Country Link
US (2) US11214620B2 (enExample)
EP (2) EP3858858A1 (enExample)
JP (2) JP7085709B2 (enExample)
KR (2) KR20190019144A (enExample)
CN (1) CN109563171B (enExample)
AR (1) AR110101A1 (enExample)
AU (1) AU2017283181B2 (enExample)
BR (1) BR112018076519A8 (enExample)
CA (1) CA3027612A1 (enExample)
CY (1) CY1124232T1 (enExample)
DK (1) DK3472207T3 (enExample)
ES (1) ES2858091T3 (enExample)
HR (1) HRP20210602T1 (enExample)
HU (1) HUE053742T2 (enExample)
IL (1) IL263730B2 (enExample)
LT (1) LT3472207T (enExample)
MX (1) MX2018016320A (enExample)
PL (1) PL3472207T3 (enExample)
PT (1) PT3472207T (enExample)
RS (1) RS61705B1 (enExample)
SG (1) SG11201811064TA (enExample)
SI (1) SI3472207T1 (enExample)
SM (1) SMT202100213T1 (enExample)
TW (1) TW201803906A (enExample)
WO (1) WO2017220569A1 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
KR102185867B1 (ko) 2016-02-06 2020-12-02 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-인-탠덤 면역글로불린 및 이의 용도
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
DK3472207T3 (da) * 2016-06-20 2021-04-12 F Star Delta Ltd Bindingsmolekyler, der binder pd-l1 og lag-3
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
CN111741976B (zh) * 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
WO2019129054A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
WO2019210848A1 (en) * 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
WO2019222575A1 (en) * 2018-05-17 2019-11-21 Immunome, Inc. Ch3 domain epitope tags
WO2019246142A1 (en) * 2018-06-18 2019-12-26 Haiming Chen Soluble bispecific fusion proteins for cancer immunotherapy
EP4512417A3 (en) 2018-07-12 2025-09-17 invoX Pharma Limited Antibody molecules that bind pd-l1 and cd137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
KR20210040080A (ko) 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
CA3117016A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
BR112020026320A2 (pt) * 2018-12-17 2021-03-30 Illumina, Inc. Células de fluxo, kits de sequenciamento e método
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP3969477A1 (en) 2019-05-14 2022-03-23 F-star Therapeutics Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
BR112022004316A2 (pt) 2019-09-22 2022-06-21 Bristol Myers Squibb Co Caracterização espacial quantitativa para terapia de antagonista lag-3
JP2022550364A (ja) * 2019-09-26 2022-12-01 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
CA3165839A1 (en) * 2019-12-23 2021-07-01 Macrogenics, Inc. Therapy for the treatment of cancer
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
EP4096789A4 (en) 2020-01-29 2023-10-11 Board of Regents, The University of Texas System USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
JP2023513006A (ja) 2020-01-29 2023-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
IL311936A (en) * 2020-05-12 2024-06-01 Astrazeneca Ab Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022047189A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
MX2023004493A (es) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
KR20230150295A (ko) 2021-01-29 2023-10-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키나제 억제제를 이용한 암의 치료 방법
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
WO2022216979A1 (en) 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20240417473A1 (en) 2021-10-29 2024-12-19 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
CN118765284A (zh) 2022-02-25 2024-10-11 百时美施贵宝公司 结直肠癌的组合疗法
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
US20250179170A1 (en) 2022-03-08 2025-06-05 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
US20230355760A1 (en) * 2022-03-10 2023-11-09 Mendus B.V. Modified cells of leukemic origin and a pd-l1 antibody for enhancing the efficacy of cancer cell therapy
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
WO2024107731A2 (en) * 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
CN120390652A (zh) 2022-12-01 2025-07-29 免疫医疗有限公司 用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
AU2023409221A1 (en) 2022-12-21 2025-06-12 Bristol-Myers Squibb Company Combination therapy for lung cancer
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
TW202535926A (zh) 2023-10-30 2025-09-16 美商再生元醫藥公司 穩定抗體配製物
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
TW202539744A (zh) 2024-02-27 2025-10-16 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體藥物軛合物
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (enExample) 1973-11-12 1978-01-23
JPS5746634B2 (enExample) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
DE602006003695D1 (de) 2005-01-05 2009-01-02 F Star Biotech Forsch & Entw Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
EA019344B1 (ru) * 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9407069B2 (en) 2014-08-10 2016-08-02 Federal-Mogul Ignition Company Spark plug with improved seal
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3292148B1 (en) 2015-05-04 2024-01-24 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
CN114181309B (zh) 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
TWI733687B (zh) 2015-07-22 2021-07-21 美商索倫多醫療公司 結合ｌａｇ３之抗體治療劑
HK1254450A1 (zh) 2015-08-07 2019-07-19 Pieris Pharmaceuticals Gmbh 对lag-3和pd-1特异性的新型融合多肽
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
HK1254951A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Pd1和/或lag3结合剂
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
CN108779176A (zh) 2016-01-11 2018-11-09 印希比股份有限公司 多价和多特异性41bb结合融合蛋白
JP2019523630A (ja) 2016-04-22 2019-08-29 アリゲーター・バイオサイエンス・アーベー Ｃｄ１３７に対する新規の二重特異性ポリペプチド
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
DK3472207T3 (da) * 2016-06-20 2021-04-12 F Star Delta Ltd Bindingsmolekyler, der binder pd-l1 og lag-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
KR20190065318A (ko) 2016-09-23 2019-06-11 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 결합 분자
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
KR102758346B1 (ko) 2017-08-04 2025-01-24 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
CN111741976B (zh) 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies

Also Published As

Publication number Publication date
IL263730B1 (en) 2024-02-01
LT3472207T (lt) 2021-05-10
US11214620B2 (en) 2022-01-04
PL3472207T3 (pl) 2021-07-12
RU2018143241A (ru) 2020-07-21
KR20190019144A (ko) 2019-02-26
KR102664891B1 (ko) 2024-05-13
MX2018016320A (es) 2019-05-30
EP3472207B1 (en) 2021-01-20
SMT202100213T1 (it) 2021-05-07
CY1124232T1 (el) 2022-05-27
EP3472207A1 (en) 2019-04-24
JP7085709B2 (ja) 2022-06-17
PT3472207T (pt) 2021-03-31
US20220185894A1 (en) 2022-06-16
SG11201811064TA (en) 2019-01-30
DK3472207T3 (da) 2021-04-12
IL263730A (en) 2019-01-31
RS61705B1 (sr) 2021-05-31
JP2019526273A (ja) 2019-09-19
IL263730B2 (en) 2024-06-01
BR112018076519A8 (pt) 2022-07-12
JP2022095746A (ja) 2022-06-28
CN109563171A (zh) 2019-04-02
KR20230035680A (ko) 2023-03-14
HRP20210602T1 (hr) 2021-05-14
CN109563171B (zh) 2023-09-19
US20190256602A1 (en) 2019-08-22
AU2017283181A1 (en) 2019-01-03
HUE053742T2 (hu) 2021-07-28
SI3472207T1 (sl) 2021-04-30
RU2018143241A3 (enExample) 2020-11-11
BR112018076519A2 (pt) 2019-04-02
CA3027612A1 (en) 2017-12-28
WO2017220569A1 (en) 2017-12-28
AU2017283181B2 (en) 2024-08-15
ES2858091T3 (es) 2021-09-29
JP7464644B2 (ja) 2024-04-09
EP3858858A1 (en) 2021-08-04
TW201803906A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
AR110101A1 (es) Miembros de unión (2)
AR111203A1 (es) Inmunoconjugados
CA3140875A1 (en) Macrophage specific engager compositions and methods of use thereof
FI3820894T3 (fi) Mesoteliinia ja vastaavasti cd137:ää sitovia molekyylejä
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
RU2015143208A (ru) Высокоаффинные антитела kgd2
JP2024542159A (ja) Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
JP2019517508A5 (enExample)
PE20211499A1 (es) Peptidos restringidos por a 03 para el uso en la inmunoterapia contra el cancer y metodos relacionados
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
RU2020115161A (ru) Днк моноклональных антител против ctla-4 для лечения и профилактики рака
AR121441A1 (es) Anticuerpos anti-axl y composiciones
JPWO2020012486A5 (enExample)
PE20241789A1 (es) Anticuerpos anti-clec12a y usos de los mismos
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso
PE20211452A1 (es) Nuevos receptores de celulas t modificados geneticamente y terapias inmunologicas que emplean los mismos
US20240327482A1 (en) Macrophage specific engager compositions and methods of use thereof
AR132062A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR132099A1 (es) Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal